Synovial Sarcoma of the Posterior Neck: A Case Report and Review of Literature

Jae-Won Jang, M.D., Jung-Kil Lee, M.D., Bo-Ra Seo, M.D., Soo-Han Kim, M.D.
Department of Neurosurgery, Chonnam National University Hospital & Medical School, Gwangju, Korea

We recently experienced a case of synovial sarcoma in the posterior neck, which involved adjacent bony structures. Synovial sarcoma is rare, malignant soft tissue tumor that occur predominantly in the lower extremities. Wide surgical excision with involved tissue is the treatment of first choice, because most synovial sarcomas reveal aggressive features. We removed the tumor with involved bony structures and patient was given postoperative radiation therapy. Despite these treatment options, the patient died 1 year after surgery. We report this case with a review of the literature.

KEY WORDS: Synovial sarcoma ˙ Posterior neck ˙ Bony involvement.

INTRODUCTION

Synovial sarcoma is an uncommon neoplasm that has been reported to account for 5% to 10% of all soft tissue sarcomas. The tumors are mainly found in para-articular regions of the lower extremities, and only 3% to 10% of all synovial sarcomas arise from the head and neck. Among these, only a few cases have been reported to originate in the posterior neck. Synovial sarcoma is usually seen in young adults (20-30 years' group), and the disease is more common in men than women with a 3 : 2 ratio. Histopathologically, synovial sarcoma shows a biphasic pattern consisting of both an epithelial round cell component and a fibrous spindle cell component. However, some tumors show a monophasic pattern, as well as myxoid, calcifying, and bone forming forms. Due to such a variety of histopathological findings, synovial sarcomas of the head and neck are confused with other mesenchymal and non-mesenchymal tumors. In addition, immunohistochemical and cytogenetic examinations are important for diagnosis.

Total surgical excision with a wide margin is a widely used treatment for synovial sarcoma, although the optimal treatment strategy has not yet been established. If risk for loco-regional recurrence is high, postoperative radiation therapy is recommended. In this article, we report on a case of posterior neck synovial sarcoma with a large size (> 5 cm) and adjacent bony involvement, with a review of the literature.

CASE REPORT

A 39-year-old man visited our hospital complaining of posterior neck pain and left shoulder pain for six months. He had no other symptoms or past medical history. Neck computed tomography (CT) was performed first and it
revealed a 5.5×4×12 cm sized non-calcified and slightly hypodense soft tissue mass in the paraspinal muscle from C3 to T3, with destructive changes of the C4-5 spinous process and lamina (Fig. 1). Cervical magnetic resonance imaging (MRI) showed mixed signal intensity in the lesion with a central cystic component (Fig. 2A). The lesion was heterogenous, and enhanced by gadolinium (Fig. 2B). Considering the CT and MRI findings, we determined that the lesion might be a malignant tumor originated in the paraspinal muscle of the posterior neck. We could remove the tumor completely as en bloc through left paraspinal approach. On operative findings, the lesion was well capsulated, soft, gray colored, and low vascular lesions. The upper part of the tumor consists of old hematoma (Fig. 3).

Histologically, the tumor was composed mainly of epithelial cells and spindle cells (Fig. 4A). Immunohistochemical staining for cytokeratin-7 showed positive findings (Fig. 4B). Neural markers showed negative findings. Based on these results, the tumor was diagnosed as a biphasic synovial sarcoma. Biopsy from surgical margin showed positive finding to tumor. Postoperative investigations of metastasis were done. Whole body positron emission tomography (PET) CT and bone scan showed no increased uptake in lesions. No abnormal metastatic lesions were seen on the chest and abdominal CT. The patient was referred to a radiation oncologist for postoperative radiation therapy. Intensity modulated radiation therapy (IMRT) was performed with total 7,000 cGy. A follow up MRI six month later showed no recurrent lesions on the previous operation site (Fig. 5A). However, PET CT showed a well defined multiple hypermetabolic nodule at both lung fields, representative of metastatic lesions (Fig. 5B). We planned adjuvant systemic chemotherapy, however the patient refused. The patient died due to metastatic complications 1 year after the surgery.

DISCUSSION

Synovial sarcoma can occur at all ages, but most frequently affects young adults and adolescents. The most common locations in the head and neck regions are the upper aerodigestive tract, parapharyngeal spaces, and joints between the cervical vertebrae. The tumor has also occurred in various other anatomic sites, including the neck, trunk, thymus, kidney, bone, skin, nervous system, liver, pleura, ovary, and mediastinum.

Synovial sarcomas are very aggressive tumors. The reported 5-year survival rate for patients with synovial sarcoma is approximately 40% to 60%. If the tumor is located in the skull base or paraspinal region, tumor size was more than 5 cm, or the tumor infiltrated adjacent structures, it has the worse prognosis. On the other hand, patients with calcification or synovial sarcoma of the upper aerodigestive tract had an excellent prognosis.

Radiologic diagnosis of synovial sarcoma is difficult. On CT findings, the tumor was shown to be slightly hypodense, well demarcated, with homogenous enhancement. However, the tumor may be seen sometimes with heterogeneous enhancement. Therefore, these results may be difficult to distinguish from benign tumors or other malignant tumors. Calcifications are seen in < 30% of all synovial sarcomas. MRI found that a head and neck synovial sarcoma on T1-weighted images is shown most frequently isointense.
to gray matter and has a signal intensity similar to that of glandular or fat tissue on T2-weighted images\(^9\). Well-demarcated, yet heterogeneous mucosal or nonmucosal lesions, containing septations, hemorrhage, internal cystic formations, calcifications, or multilocularity, can also be seen in synovial sarcoma\(^9\). However, there is no definitive characteristic finding in terms of density and intensity, then radiologic diagnosis is uncertain\(^{16}\).

Histopathological examination and immunohistochemical staining are very important to the diagnosis of synovial sarcoma due to radiologic uncertainty. Histopathologically, synovial sarcoma shows a biphasic pattern consisting of both epithelial and spindle cells. Some tumors show monophasic patterns consisting of only 1 component\(^{11,15}\). Clinical features were different between biphasic and monophasic tumors. Monophasic tumors tended to present at sizes of < 5 cm, while biphasic tumors tend to present at sizes of > 5 cm. Biphasic tumors were more likely tended to infiltrate bone. However, no differences were found in demographic characteristics and history of prior radiation exposure\(^{8,14}\).

Immunohistochemical staining has also been a useful diagnostic tool, because synovial sarcoma can be found in unexpected locations and morphology can vary. Most synovial sarcomas are immunoreactive for cytokeratin, epithelial membrane antigen, and bcl-2. Tumors may express S100 protein, and CD99. However, immunoreactivity for CD34 is not expressed\(^{6,15}\).

Cytologic study is helpful for the diagnosis of synovial sarcoma. Ninety percent of synovial sarcomas have an identifiable translocation between chromosomes 18 and X that result in the fusion of the SYT gene on chromosome 18 and the SSX-1 or SSX-2 gene on chromosome X\(^{1,8,13,15}\). Tumors with the SYT-SSX2 gene fusion transcript type showed higher survival rates and better metastasis-free survival rates than the tumor with the SYT-SSX1 gene fusion transcript type. Therefore, cytologic study can be a prognostic factor as well as definitive a diagnostic tool\(^{13,15}\).

The first optimal treatment strategy for synovial sarcoma is surgical excision with negative margins\(^{7,18}\). Additional radiation therapy in the management of synovial sarcoma has been shown to improve local control as compared with surgery alone\(^{14}\). However, there was no significant difference in disease free survival or local control between preoperative and postoperative radiation therapy\(^{6}\). Patients treated with radiation therapy after surgical excision had higher survival and lower recurrence rates than those treated with chemotherapy after surgical excision\(^9\). The role of chemotherapy has not yet been established, although intensive systemic chemotherapy with cisplatin, adriamycin, ifosfamide, and other chemotherapeutic agents was performed in many cases\(^{15}\). Recently, among patients with synovial sarcoma undergoing resection with curative intent, anthracycline-ifosfamide (AI) chemotherapy was associated with improved survival in a retrospective analysis\(^9\). Canter et al.\(^8\) suggested that a nomogram based on preoperative variables may im-
prove decision-making with regards to selecting patients most likely to benefit from neoadjuvant/adjuvant chemotherapy. Therefore, we think systemic chemotherapy will play an important role in the treatment for control of distant metastasis of synovial sarcomas.

In our case, there were many poor prognostic factors. These were the tumor larger than 5 cm, paraspinal location, internal hemorrhage, and adjacent bony destruction with invasion. However, we performed only surgical resection and postoperative radiation therapy. Eventually, the patient died 1 year after the surgery due to distant pulmonary metastasis. Therefore, we think that if immediately adjuvant chemotherapy was planned and performed, the prognosis might have been the better.

CONCLUSION

Synovial sarcoma is an aggressive tumor, and survival rates are associated with tumor location, size, histologic differentiation and adjacent bony extension. Considering our case, we suggest that synovial sarcoma with known poor prognostic factors should be treated earlier with multimodality approaches, including surgery, radiation therapy, and chemotherapy, with frequent follow up examinations. Finally, the tumor should be included in the differential diagnosis of posterior neck soft tissue.

References
1. Alektiar KM, Leung D, Zelefsky MJ, Brennan MF: Adjuvant radiation for stage II-B soft tissue sarcoma of the extremity. J Clin Oncol 20: 1643-1650, 2002
2. Bergh P, Meis-Kindblom JM, Gherlinzoni F, Berlin O, Bacchini P, Berthon F, et al.: Synovial sarcoma: identification of low and high risk groups. Cancer 85: 2596-2607, 1999
3. Canter RJ, Qin LX, Maki RG, Brennan MF, Ladanyi M, Singer S: A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res 14: 8191-8197, 2008
4. Davis AM, O’Sullivan B, Turcotte R, Bell R, Carton C, Chabot P, et al.: Late radiation morbidity following randomization to neoadjuvant versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol 75: 48-53, 2005
5. Eilber FC, Brennan MF, Eilber FR, Eckardt, JJ, Grobmyer SR, Riedel E, et al.: Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg 246: 105-113, 2007
6. Fisher C: Synovial sarcoma. Ann Diag Pathol 2: 401-421, 1998
7. Gronchi A, Casali PG, Mariani L, Miceli R, Fiore M, Lo Vullo S, et al.: Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J Clin Oncol 23: 96-104, 2005
8. Harb WJ, Luna MA, Patel SR, Ballo MT, Roberts DB, Sturgis EM: Survival in patients with synovial sarcoma of the head and neck: association with tumor location, size, and extension. Head Neck 29: 731-740, 2007
9. Hirsch RJ, Yousem DM, Loewner LA, Montone KT, Chalian AA, Hayden RE, et al.: Synovial sarcomas of the head and neck: MR findings. AJR Am J Roentgenol 169: 1185-1188, 1997
10. Holla P, Hafez GR, Slukvin I, Kalayoglu M: Synovial sarcoma, a primary liver tumor—a case report. Pathol Res Pract 202: 385-387, 2006
11. Ishiki H, Miyajima C, Nakao K, Asakage T, Sugawara M, Motoi T: Synovial sarcoma of the head and neck: rare case of cervical metastasis. Head Neck 31: 131-135, 2009
12. Jang KS, Min KW, Jang SH, Paik SS, Tae K, Jang SJ, et al.: Primary synovial sarcoma of the thyroid gland. J Korean Med Sci 22 Suppl: S154-158, 2007
13. Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M: SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 338: 153-160, 1998
14. Lee N, Shin E: Treatment outcomes for patients with synovial sarcoma of the head and neck. Expert Rev Anticancer Ther 8: 371-373, 2008
15. Ochi N, Uozumi M, Doi K, Tanimoto H, Ohlayashi C, Inagaki H, et al.: Synovial sarcoma of the neck. ORL J Otorhinolaryngol Relat Spec 66: 42-45, 2004
16. Rangheard AS, Vanel D, Viala J, Schwab G, Casiraghi O, Sigal R: Synovial sarcomas of the head and neck: CT and MR imaging findings of eight patients. AJNR Am J Neuroradiol 22: 851-857, 2001
17. Smith CJ, Ferrier AJ, Russell P, Danieleto S: Primary synovial sarcoma of the ovary: first reported case. Pathology 37: 385-387, 2005
18. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, et al.: Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer 97: 2530-2543, 2003